Wordt geladen...
Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer
BACKGROUND: High-dose intravenous immunoglobulin (IVIg), and more recently, subcutaneously-delivered Ig (SCIg), are used to treat a variety of autoimmune diseases; however, there are challenges associated with product production, availability, access and efficacy. These challenges have provided ince...
Bewaard in:
| Gepubliceerd in: | BMC Immunol |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6894239/ https://ncbi.nlm.nih.gov/pubmed/31801459 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12865-019-0328-6 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|